2. Search Result
Search Result
Results for "

intestinal barrier integrity

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

6

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13771A
    Ursodeoxycholic acid sodium
    15+ Cited Publications

    Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium

    		 G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite Metabolic Disease Inflammation/Immunology Cancer
    Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
    Ursodeoxycholic acid sodium
  • HY-13771
    Ursodeoxycholic acid
    15+ Cited Publications

    Ursodeoxycholate; Ursodiol; UDCA

    		 G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Infection Metabolic Disease Cancer
    Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
    Ursodeoxycholic acid
  • HY-13771R
    Ursodeoxycholic acid (Standard)

    Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)

    		 Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Infection Metabolic Disease Cancer
    Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
    Ursodeoxycholic acid (Standard)
  • HY-I0746
    3-Aminobenzoic acid

    m-Aminobenzoic acid; 3ABA

    		 Endogenous Metabolite Neurological Disease Inflammation/Immunology
    3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
    3-Aminobenzoic acid
  • HY-N2468
    Xylobiose

    1,4-β-D-Xylobiose; 1,4-D-Xylobiose

    		 TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose
  • HY-N2468R
    Xylobiose (Standard)

    		TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose (Standard)
  • HY-I0746R
    3-Aminobenzoic acid (Standard)

    m-Aminobenzoic acid (Standard); 3ABA (Standard)

    		 Reference Standards Endogenous Metabolite Neurological Disease Inflammation/Immunology
    3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
    3-Aminobenzoic acid (Standard)
  • HY-N1516R
    Ganoderenic acid D (Standard)

    		Reference Standards Apoptosis Cancer
    3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
    Ganoderenic acid D (Standard)
  • HY-13771S1
    Ursodeoxycholic acid-13C

    Ursodeoxycholate-13C; Ursodiol-13C; UDCA-13C

    		 Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite Cancer
    Ursodeoxycholic acid- 13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
    Ursodeoxycholic acid-13C
  • HY-176554
    sEH-IN-21

    		Epoxide Hydrolase NF-κB Interleukin Related TNF Receptor Metabolic Disease Inflammation/Immunology
    sEH-IN-21 is an orally active sEH inhibitor with IC50s of 0.1 nM for hsEH and msEH. sEH-IN-21 potently inhibits NF-κB signaling pathways. sEH-IN-21 shows a strong anti-inflammatory activity, decreases the release of IL-6 and TNF-α and maintained the integrity of the intestinal barrier. sEH-IN-21 can be used for the study of inflammatory bowel disease (IBD) .
    sEH-IN-21
  • HY-113478S
    Ursodeoxycholic acid-2,2,4,4-d4

    		Isotope-Labeled Compounds Infection Metabolic Disease
    Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .
    Ursodeoxycholic acid-2,2,4,4-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: